Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chronic lymphocytic leukemia

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129:2224–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al. Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372:1430–40.

    Article  CAS  PubMed  Google Scholar 

  3. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31:833–43 e835.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ghez D, Calleja A, Protin C, Baron M, Ledoux MP, Damaj G, et al. Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib. Blood. 2018;131:1955–9.

    Article  CAS  PubMed  Google Scholar 

  7. Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128:1940–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Varughese T, Taur Y, Cohen N, Palomba ML, Seo SK, Hohl TM, et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid malignancies. Clin Infect Dis. 2018;67:687–92.

  9. Bercusson A, Colley T, Shah A, Warris A, Armstrong-James D. Ibrutinib blocks Btk-dependent NF-kB and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood. 2018;132:1985–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.

    Article  PubMed  Google Scholar 

  11. Tuccori M, Focosi D, Blandizzi C, Pelosini M, Montagnani S, Maggi F, et al. Inclusion of rituximab in treatment protocols for non-Hodgkin’s lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist. 2010;15:1214–9.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Lecube A, Pachon G, Petriz J, Hernandez C, Simo R. Phagocytic activity is impaired in type 2 diabetes mellitus and increases after metabolic improvement. PloS ONE. 2011;6:e23366.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Uribe-Querol E, Rosales C. Control of phagocytosis by microbial pathogens. Front Immunol. 2017;8:1368.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Albillos A, Lario M, Alvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. J Hepatol. 2014;61:1385–96.

    Article  CAS  PubMed  Google Scholar 

  15. Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw: JNCCN. 2016;14:882–913.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We would like to thank the Ohio State University Division of Hematology for support of this project. We would also like to acknowledge our colleagues who provided the clinical care for the included patients. Research reported in this publication was supported in part by the Ohio State University Comprehensive Cancer Center and the National Institutes of Health under grant number P30 CA016058. This work was also supported in part by K23 CA178183, R01 CA197870, and R35 CA197734.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jennifer A. Woyach.

Ethics declarations

Conflict of interest

The authors have the following disclosures: KAR received research funding from Genentech and consults for Acerta Pharma. SAB is on a speakers’ bureau for Janssen and Pharmacyclics. JCB receives research funding from Genentech, Acerta Pharma, Pharmacyclics, and Janssen. JAW received honoraria from Janssen, has consulted for Janssen, and receives research funding from MorphoSys, Karyopharm Therapeutics, and AbbVie. FTA has consulted for AbbVie, Gilead Sciences, AstraZeneca, Sunesis, Genentech, and Janssen, served on the speakers’ bureau for Abbvie and AstraZeneca, and received research funding from Pharmacyclics. LM, QZ, TEW, ZEB, TG, LBL, FL, PS, AS, and MS declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rogers, K.A., Mousa, L., Zhao, Q. et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. Leukemia 33, 2527–2530 (2019). https://doi.org/10.1038/s41375-019-0481-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-019-0481-1

This article is cited by

Search

Quick links